NO20060398L - Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft - Google Patents

Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft

Info

Publication number
NO20060398L
NO20060398L NO20060398A NO20060398A NO20060398L NO 20060398 L NO20060398 L NO 20060398L NO 20060398 A NO20060398 A NO 20060398A NO 20060398 A NO20060398 A NO 20060398A NO 20060398 L NO20060398 L NO 20060398L
Authority
NO
Norway
Prior art keywords
cancer
inhibition
treatment
kinase inhibitor
combination
Prior art date
Application number
NO20060398A
Other languages
English (en)
Inventor
Phillip Frost
Mary Carolyn Discafani-Marro
Lee Martin Greenberger
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20060398L publication Critical patent/NO20060398L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse beskriver kombinasjoner omfattende et cytotoksisk middel og en EGFR-kinase-inhibitor og metoder for behandling eller hemning av kreft hos et pattedyr med behov for dette, som omfatter administrering til nevnte pattedyr av en effektiv mengde av et cytotoksisk middel og en EGFR-kinase-inhibitor.
NO20060398A 2003-08-01 2006-01-25 Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft NO20060398L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49213203P 2003-08-01 2003-08-01
PCT/US2004/024478 WO2005018677A2 (en) 2003-08-01 2004-07-28 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer

Publications (1)

Publication Number Publication Date
NO20060398L true NO20060398L (no) 2006-02-28

Family

ID=34215843

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060398A NO20060398L (no) 2003-08-01 2006-01-25 Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft

Country Status (19)

Country Link
US (1) US20050026933A1 (no)
EP (1) EP1648516A2 (no)
JP (1) JP2007501238A (no)
KR (1) KR20060054412A (no)
CN (1) CN1832757A (no)
AR (1) AR045179A1 (no)
AU (1) AU2004266572A1 (no)
BR (1) BRPI0413255A (no)
CA (1) CA2533126A1 (no)
CO (1) CO5640151A2 (no)
CR (1) CR8181A (no)
EC (1) ECSP066341A (no)
IL (1) IL173081A0 (no)
MX (1) MXPA06001110A (no)
NO (1) NO20060398L (no)
RU (1) RU2006106267A (no)
TW (1) TW200515910A (no)
WO (1) WO2005018677A2 (no)
ZA (1) ZA200600915B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0308410A (pt) * 2002-03-29 2005-01-18 Exxonmobil Chem Patents Inc Preparação de hidrocarbonetos aromáticos e sulfonatos de alquilarila
EP1494983A1 (en) * 2002-03-29 2005-01-12 ExxonMobil Chemical Patents, Inc. a Corporation of the State of Delaware Oligomerization of olefins
EP2439284B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
MXPA06014002A (es) * 2004-06-03 2007-02-08 Hoffmann La Roche Tratamiento con cisplatina y un inhibidor de cinasa del receptor del factor de crecimiento epidermico (egfr).
RU2006146623A (ru) * 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение оксалиплатином и ингибитором рецептора эпидермального фактора роста (egfr)
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
JP2008538282A (ja) 2005-04-05 2008-10-23 セルポイント ダイアグノスティクス， インコーポレイテッド 装置および循環腫瘍細胞および他の粒子の濃縮および変更のための方法
MX2007012662A (es) * 2005-04-14 2008-04-04 Wyeth Corp Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib.
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
EP2428213A1 (en) * 2005-07-21 2012-03-14 Nuvo Research AG Stabilized chlorite solutions in combination with fluoropyrimidines for use in cancer treatment
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US8143447B2 (en) * 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
US7994222B2 (en) * 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
JP2010503696A (ja) * 2006-09-13 2010-02-04 ヌベロ， インコーポレイテッド 癌を処置するための方法
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2008321128A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CN101918003A (zh) * 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌
CN101888777A (zh) * 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
CN115990181A (zh) * 2008-08-04 2023-04-21 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
WO2010028236A1 (en) * 2008-09-05 2010-03-11 Avila Therapeutics, Inc. Algorithm for designing irreversible inhibitors
CA2755789C (en) 2009-04-06 2016-01-19 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
NZ620174A (en) * 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
WO2011082285A1 (en) 2009-12-30 2011-07-07 Avila Therapeutics, Inc. Ligand-directed covalent modification of protein
JP6474166B2 (ja) 2014-01-01 2019-02-27 メディベイション テクノロジーズ エルエルシー 化合物及び使用方法
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
BR0214485A (pt) * 2001-11-27 2004-09-14 Wyeth Corp 3-cianoquinolinas como inibidores de egf-r e her2 quinases

Also Published As

Publication number Publication date
MXPA06001110A (es) 2006-04-11
BRPI0413255A (pt) 2006-10-03
ECSP066341A (es) 2006-08-30
CO5640151A2 (es) 2006-05-31
CR8181A (es) 2006-07-14
WO2005018677A3 (en) 2006-05-26
WO2005018677A2 (en) 2005-03-03
JP2007501238A (ja) 2007-01-25
AU2004266572A1 (en) 2005-03-03
TW200515910A (en) 2005-05-16
RU2006106267A (ru) 2006-07-27
AR045179A1 (es) 2005-10-19
CN1832757A (zh) 2006-09-13
IL173081A0 (en) 2006-06-11
KR20060054412A (ko) 2006-05-22
CA2533126A1 (en) 2005-03-03
ZA200600915B (en) 2007-12-27
EP1648516A2 (en) 2006-04-26
US20050026933A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
ECSP055525A (es) Inhibidores de cinasas de tirosina
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
EA200801118A1 (ru) Способ ингибирования flt3 киназы
ZA200703196B (en) Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
PE20040990A1 (es) Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos
EA200870454A1 (ru) Способ ингибирования c-kit киназы
ATE424208T1 (de) Proteinkinaseinhibitoren
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
WO2008036254A3 (en) Autophagic compounds and tyrosine kinase inhibitors for treating cancer
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application